منابع مشابه
Imatinib mesylate-induced lichenoid drug eruption.
Imatinib mesylate (imatinib) is a tyrosine kinase inhibitor initially approved by the US Food and Drug Administration in 2001 for chronic myeloid leukemia (CML). Since then, the number of indicated uses for imatinib has substantially increased. It is increasingly important that dermatologists recognize adverse cutaneous manifestations of imatinib and are aware of their management and outcomes t...
متن کامل[Lichenoid drug eruption induced by olanzapine].
Lichenoid drug eruptions can mimic idiopathic lichen planus and other dermatoses. The list of drugs that can cause them is long and growing steadily. Although cutaneous side effects of antipsychotics are rare, various cutaneous manifestations have been reported in association with olanzapine. We present the case of a patient who developed an atypical lichenoid eruption due to olanzapine. A revi...
متن کاملFenofibrate-Induced Lichenoid Drug Eruption: A Rare Culprit
A lichenoid drug eruption is a rare side effect which can occur following the administration of several different medications. Here we describe a unique case of fenofibrate as the causative agent of a lichenoid drug eruption. This case highlights a rare and clinically significant dermatologic side effect of fenofibrate. In addition, we report a potential familial association which underscores t...
متن کاملLichenoid drug eruption due to eprosartan/hydrochlorothiacide
We report a case of a 66-year-old male who developed an itchy eruption while taking an antihypertonic drug containing eprosartan and hydrochlorothiacide after sun exposure. The lesions resembled a lichenoid appearance that was confirmed by the histological study. There are few reports in the literature of lichenoid reactions to these compounds, so we review the characteristics of themselves as ...
متن کاملLichenoid drug eruption associated with Bendamustine
A 65-year-old man had relapsed follicular lymphoma. When he suffered a fifth relapse, he received a regimen containing bendamustine and rituximab (BR). Four weeks later, he presented with systemic erythema, swelling and bullous lesions of lips, the oral cavity, andnasal mucosa and eye pain. He could not open his mouth and had severe pain. Steven–Johnson syndrome/toxic epidermal necrolysis was d...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Avicenna Journal of Medicine
سال: 2015
ISSN: 2231-0770
DOI: 10.4103/2231-0770.160250